Logotype for InMed Pharmaceuticals Inc

InMed Pharmaceuticals (INM) Q1 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for InMed Pharmaceuticals Inc

Q1 2027 earnings summary

4 Nov, 2026

Executive summary

  • Q1 FY2027 net loss was $2.331M versus $1.727M a year earlier; cash and cash equivalents were $1.094M at September 30, 2026.

  • Operations are focused on pharmaceutical R&D after BayMedica Commercial wound down; significant resources are not currently planned for advancing drug candidates.

  • Proposed Mentari merger and ~US$490M in private-placement financing are central to the outlook; proposed CVRs could provide eligible shareholders with proceeds from future legacy-asset monetization, but none are assured.

Financial highlights

  • Continuing-operations net loss was $1.995M versus $1.830M; total net loss included a $336K discontinued-operations loss versus $103K income a year earlier.

  • Continuing-operations operating expenses were $2.009M, up 4% YoY; R&D expense fell 64% to $206K, while G&A rose 46% to $1.803M, primarily on merger costs.

  • Basic and diluted loss per share was $0.42 versus $0.44 YoY; continuing-operations loss per share was $0.36 versus $0.46.

  • Cash used in operating activities was $1.142M versus $1.931M a year earlier; quarter-end cash and cash equivalents were $1.094M versus $2.194M at June 30, 2026.

Outlook and guidance

  • Available cash was expected to fund planned operating and capital needs into mid-November, subject to spending and merger timing; additional capital is required to sustain operations.

  • Merger closing was expected in Q4 2026, subject to closing conditions and required approvals; Mentari financing is intended to support operations into 2029 and through Phase 2a readouts for two lead PACAP-targeted programs.

  • If the merger does not close, funding or strategic transactions may be pursued; capital may not be secured on acceptable terms or at all.

  • If the merger does not proceed and funding is obtained, R&D expense is expected to rise substantially; no material product-candidate revenue is expected for several years, if ever.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from InMed Pharmaceuticals